These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 24215016

  • 1. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T, Birn H, Bibby BM, Regeniter A, Sørensen SS, Feldt-Rasmussen U, Nielsen R, Christensen EI.
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [Abstract] [Full Text] [Related]

  • 2. New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study.
    Aguiar P, Azevedo O, Pinto R, Marino J, Baker R, Cardoso C, Ducla Soares JL, Hughes D.
    Mol Genet Metab; 2017 Jun; 121(2):162-169. PubMed ID: 28526293
    [Abstract] [Full Text] [Related]

  • 3. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
    Waldek S, Feriozzi S.
    BMC Nephrol; 2014 May 06; 15():72. PubMed ID: 24886109
    [Abstract] [Full Text] [Related]

  • 4. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH, Lee BH, Hyang Cho J, Kang E, Choi JH, Kim GH, Yoo HW.
    J Hum Genet; 2016 Nov 06; 61(11):923-929. PubMed ID: 27334365
    [Abstract] [Full Text] [Related]

  • 5. The kidney in Fabry's disease.
    Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, Riccio E.
    Clin Genet; 2014 Oct 06; 86(4):301-9. PubMed ID: 24645664
    [Abstract] [Full Text] [Related]

  • 6. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
    Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, Paulero M, Rengel T, Aráoz A, Forrester M, Lombi F, Pomeranz V, Iriarte R, Young P, Muryan A, Zotta E.
    J Nephrol; 2016 Dec 06; 29(6):791-797. PubMed ID: 26842625
    [Abstract] [Full Text] [Related]

  • 7. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
    Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, Fabry Registry.
    Nephrol Dial Transplant; 2008 May 06; 23(5):1600-7. PubMed ID: 18175781
    [Abstract] [Full Text] [Related]

  • 8. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
    Moura AP, Hammerschmidt T, Deon M, Giugliani R, Vargas CR.
    Clin Chim Acta; 2018 Mar 06; 478():62-67. PubMed ID: 29274327
    [Abstract] [Full Text] [Related]

  • 9. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.
    Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA, Pastores GM, Logan S.
    J Inherit Metab Dis; 2014 Nov 06; 37(6):969-78. PubMed ID: 24831586
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 11. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
    Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, Gurevich A, Ramaswami U, FOS Study Group.
    Drug Des Devel Ther; 2020 Jun 07; 14():2149-2158. PubMed ID: 32581513
    [Abstract] [Full Text] [Related]

  • 12. Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
    Kume S, Yasuda-Yamahara M, Imamura-Uehara Y, Kuwagata S, Yamahara K, Takeda N, Chin-Kanasaki M, Kato K, Ohno S, Nakagawa Y, Maegawa H.
    Intern Med; 2022 Oct 15; 61(20):3077-3081. PubMed ID: 35283375
    [Abstract] [Full Text] [Related]

  • 13. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH.
    PLoS One; 2010 Nov 24; 5(11):e15033. PubMed ID: 21124789
    [Abstract] [Full Text] [Related]

  • 14. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
    Chen Z, Yin B, Jiao J, Ye T.
    BMC Nephrol; 2024 Feb 21; 25(1):61. PubMed ID: 38383316
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ, Banikazemi M, Wasserstein M.
    Clin Nephrol; 2002 Jan 21; 57(1):1-8. PubMed ID: 11837797
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
    Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, Maguire G, Wright N, Cox TM, Meikle PJ, Deegan PB.
    J Inherit Metab Dis; 2005 Jan 21; 28(1):21-33. PubMed ID: 15702403
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini CM, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymanska A, Bénichou B, Wijburg FA.
    Mol Genet Metab; 2019 May 21; 127(1):86-94. PubMed ID: 30987917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.